Diabetic Drug, Liraglutide, Now Available to Qualified Diet Doc Patients as Part of Their Personalized Weight Loss Treatment Programs
Because many diabetic patients who were prescribed the injectable diabetic drug, Liraglutide, marketed under the name, Saxenda, reported weight loss, the drug is now being used to treat patients whose weight has gotten out of control. Diet Doc patients who have a body mass index (BMI) of 30 or greater or those patients with a BMI of 27 with one or more weight-related condition, such as high blood pressure, may be eligible to add the diabetic drug, Liraglutide, to their...
View full press release